---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-048593"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2023-09-18T23:59:59+00:00"
generated_at: "2026-06-10T14:40:13.845861+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kintara Therapeutics FY2023 net loss $14.6M, cash $1.5M; VAL-083 data expected by year-end

## Summary
- Net loss $14.6M ($9.27/share) vs $22.7M ($25.80) in FY2022; R&D fell to $9.3M from $15.2M.
- Cash and equivalents $1.5M at June 30, 2023, down from $11.8M; working capital $188K.
- Awarded $2.0M NIH SBIR grant for REM-001; first patient in 15-patient study expected Q4 2023.
- Top-line data from VAL-083 GBM AGILE registrational study anticipated before end of calendar 2023.
- General and administrative costs decreased to $5.5M from $7.5M due to reduced staffing.

## SEC filing metadata
- accession: 0000950170-23-048593
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2023-09-18T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017023048593/0000950170-23-048593-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017023048593/ktra-20230918.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-048593
- JSON: https://secwatch.observer/filing/0000950170-23-048593.json
- Plain text: https://secwatch.observer/filing/0000950170-23-048593.txt

## Key facts
- Earnings Releases
  TuHURA Biosciences, Inc./NV reported the fiscal year ended June 30, 2023 results: net income a net loss of approximately $14.6 million, or $9.27 per share, EPS $9.27 per share.
  - Period: the fiscal year ended June 30, 2023
  - Net income: a net loss of approximately $14.6 million, or $9.27 per share
  - EPS: $9.27 per share
  - Result: reported results
  source text: For the year ended June 30, 2023, Kintara reported a net loss of approximately $14.6 million, or $9.27 per share, compared to a net loss of approximately $22.7 million, or $25.80 per share, for the year ended June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000095017023048593/0000950170-23-048593-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.